HC Wainwright Reaffirms Buy Rating for Oculis (NASDAQ:OCS)

HC Wainwright restated their buy rating on shares of Oculis (NASDAQ:OCS) in a research note released on Monday,Benzinga reports. They currently have a $30.00 price target on the stock.

Oculis Stock Performance

OCS opened at $14.79 on Monday. The firm’s fifty day simple moving average is $14.20 and its two-hundred day simple moving average is $12.68. Oculis has a 52-week low of $9.60 and a 52-week high of $18.00. The company has a market cap of $599.00 million, a price-to-earnings ratio of -7.66 and a beta of -0.16. The company has a quick ratio of 5.27, a current ratio of 4.02 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.13). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. The company had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $0.28 million. Equities analysts anticipate that Oculis will post -2.1 earnings per share for the current fiscal year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.